To obtain access to any datasets listed on this site, you must first receive approval from NIDA Datashare's Data Access Committee (DAC).

Please submit your request by sending your request to NIDA_Datashare_DAC@mail.nih.gov along with the following information:

  • Your name, title, and organization
  • Study Number and Study Title
  • The specific dataset(s) you are requesting
  • The intended use or purpose of the data
  • Willingness to comply with the NIDA Datashare Registration Agreement
Once your request is reviewed, you will receive instructions on how to proceed.

Thank you for your cooperation.

NIDA-CSP-1033

Division
DTMC
HEAL Study
No
Investigator(s)
Shwe Gyaw, M.D.
Title
Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder
Short Description
The objective of this study is to evaluate the efficacy and safety of lorcaserin in the treatment of cocaine use disorder.
Release Date
Jul 19, 2024
Description
This is a 19-week, multi-center, parallel group study that includes: 1) up to 3 weeks for screening; 2) a 13-week Treatment Phase consisting of a 1-week, single-blind run-in period, when all subjects receive twice daily 15 mg acetazolamide capsules (a medication adherence marker), followed by randomization to either twice daily 10 mg lorcaserin or placebo capsules for the remaining 12 weeks; and 3) a 3-week follow-up period, with scheduled visits during Study Weeks 14 and 16.
Keywords
acetazolamide
cocaine
lorcaserin
Assessments
Urine Cocaine Level
Urine Toxicology Screen
Substance Use Report
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links
Primary Manuscript
CSP1033 Study Publication
ClinicalTrials.gov Link
CSP-1033 in NIH clinical trials registry